Group items matching

in title, tags, annotations or url

The Royal Pharmaceutical Society is set to cease all its remaining financial investments in fossil fuels latest by the end of 2022. The decision taken today (November 17) at the RPS Assemble, is part of the organisation's "continued drive to become an environmentally responsible organisation." Calling it a significant move, RPS president Claire Anderson said: "RPS will divest from fossil fuels as soon as possible. "RPS will instruct its investment managers immediately to ensure that we will be completely disinvested by the end of 2022 and hopefully sooner." Environment and human wellbeing have always been a core consideration of RPS investment, however it was not enough to offset the negative impacts of climate change, the organisation said.

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted the following price concessions for November 2021. Contractors can find information on the price concessions and learn about the process involved on PSNC's website. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted. PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2021 Drug Tariff price.

Regular blood testing is a crucial element in making sure you are healthy. Consecutive blood tests allow you to keep track of how your body changes over time while helping you make informed decisions regarding your health. WHAT DO BLOOD TESTS SHOW? Blood tests are designed to help your doctor see how your organs work. Some organ functions that can be detected with blood testing include your kidneys, liver, and thyroid. Your doctor will also use blood tests for finding disease markers and signs of other health conditions, such as HIV, diabetes, coronary heart disease, cancer, and anemia. Even if you don't have heart disease, blood tests can tell you if you are at risk of developing this condition. Other blood tests are used to determine if the medications you take work properly and to see how well your blood clots. Keep reading to learn more about the most important blood tests. You can also find out more about these when you contact NovoPath.

An international specialty pharmaceutical group, Essential Pharma has announced the completion of two transactions with fellow UK-based Rosemont Pharmaceuticals. The company completed the divestment of its oral liquid portfolio to Rosemont, and acquired a series of attractive, niche products with "geographic expansion potential." Commenting on the announcement, Essential Pharma chief executive Steen Vangsgaard said: "The Rosemont products bring additional niche products into our portfolio with international expansion potential. "The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international specialty pharma platform." Under the divestment deal, Rosemont Pharmaceuticals will acquire the product portfolio of licences, registrations and trademarks, as well as related commercial rights, to a number of oral generic products which are used to treat a range of conditions in various therapeutic areas.

Hypovase (prazosin) 500 microgram tablets, manufactured by drug major Pfizer, will remain out of stock until mid-January 2022 due to a manufacturing issue. The Department of Health and Social Care (DHSC) and NHS England and Improvement (NHSE&I) have issued a supply disruption alert for the medicine that is used to treat heart-related troubles. Pfizer, the sole supplier of prazosin 500mg tablets in the UK, is out of stock from late November 2021, and had discontinued the Hypovase® (prazosin) 1mg tablets in May 2021. Advice for healthcare professionals In the given situation, prescribers need to review all affected patients to discuss management plans. Meanwhile, alternative medicine alpha blockers remain available to support an uplift in demand.

There is no sign of a surge of the Omicron coronavirus variant in Britain so far, the chief of the UK Health Security Agency said on Tuesday, adding that there was no rise in the proportion of tests with a quirk that distinguishes it from Delta. Jenny Harries said there were five confirmed Omicron cases in England and 10 "highly likely" cases, but that was not a sign of an increase in "S-gene target failure" in PCR tests in Britain, which is a feature of Omicron. "Right across the country we watch for… S-gene target failure, which is a sort of proxy measure," Harries told BBC radio. Cases with S-gene target failure can then be prioritised for full genomic sequencing.

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron. The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were genetically compatible with the Delta variant. "To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said. Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to understand it better. There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

Homecare.co.uk's famed Top 20 UK awards have turned out a multiple winner, with Blue Angel Care a highlight. Blue Angel Care took two prestigious gongs , Top 20 Homecare Group Provider in the UK and Top 20 Home Care Providers in South East England. Finding innovative ways to circumnavigate the difficulties of the coronavirus pandemic, the homecare specialists have grown to a nationwide team of more than 200 care givers. Dariusz Motka, Managing Director and Co-Founder of Blue Angel Care, said in a statement: "We are eternally grateful to the readers and reviewers of Homecare.co.uk for honouring us with, not one, but two awards." Praising his staff, Dariusz added : "More so, we are all grateful to the incredibly hardworking and professional staff that help to train so many capable carers every single week."

Head injuries are a serious matter. They can lead to long-term health problems and even death in some cases. This article will go over some unexpected scenarios that often lead to head injuries. AIRBAG DEPLOYMENT Car accidents occur often, and you probably think you're safe from minor ones if you have your seatbelt strapped in. However, many people have suffered airbag injuries from a car accident because of their position at the moment it deployed. This may not seem like a big deal, but airbags inflate quickly, at around 200 miles per hour, and with great force. If your head is too close to the airbag when it deploys, you can suffer from some serious injuries. So what can you do to avoid this? First, make sure that you're sitting in an upright position with plenty of space between you and the steering wheel. Additionally, try to keep your headrest in an upright position so that it can provide some support if an accident does occur. And finally, be aware of airbag deployment times; they typically deploy within 0.08-0.14 seconds after an impact occurs.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have authorised community pharmacies throughout the UK to dispense original full packs of Valproate-containing medicines upon prescription. The necessary changes in regulations came into effect on 11 October which was strongly supported by 85 per cent of respondents concerned about risks to the unborn baby if valproate-containing medicines are used in pregnancy. The decision was made to ensure patients receive safety warnings and pictograms, including a patient card and the Patient Information Leaflet (PIL), contained in the manufacturer's original full pack. Valproate is a treatment for epilepsy and bipolar disorder but is also associated with birth defects and neurological disabilities.

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

The Medicines and Healthcare products Regulatory Agency (MHRA) has been accepted as a full member of three international work-sharing partnerships. Through these partnerships the agency said it will play vital international role in making sure medicines and medical devices are regulated safely and efficiently worldwide, Two of these, the International Medical Device Regulatory Forum (IMDRF) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are focused on improving the harmonisation and convergence of medicines and medical devices regulation globally. The partnerships will also help the MHRA to share expertise with other leading organisations, support the development of regulatory guidelines and drive greater harmonisation of regulation around the world. This will help deliver timely access to innovative medical products not just in the UK but globally.

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.

Established in 1907, Jakemans prides itself as one of the most popular mentholated lozenge brands[1]. Naturally infused with menthol, an ingredient that releases natural vapours to ease the symptoms of a sore throat to keep airways clear, Jakemans has been soothing sore throats and coughs for over 100 years. Using only the finest natural ingredients, Jakemans contain no artificial colours or flavours and are suitable for vegetarians. In January 2023, Jakemans will be launching a new sugar free variant of the much-loved classic flavour, Throat & Chest in a 50g bag format. Jakemans uses only the finest natural ingredients, contain no artificial colours or flavours and are suitable for vegetarians. Each tasty lozenge is bursting with menthol - an ingredient that releases natural vapours to soothe the symptoms of a sore or tickly throat and keep airways clear.

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has raised concerns within the healthcare community. This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024. Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in managing conditions like attention deficit hyperactivity disorder (ADHD). However, the scarcity of these specific strengths poses challenges for patients reliant on this medication. Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including the UK, the US and Australia. Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand, potentially resulting in treatment interruptions for patients.